|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: CYP2J2 |
Gene summary for CYP2J2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | CYP2J2 | Gene ID | 1573 |
| Gene name | cytochrome P450 family 2 subfamily J member 2 | |
| Gene Alias | CPJ2 | |
| Cytomap | 1p32.1 | |
| Gene Type | protein-coding | GO ID | GO:0001676 | UniProtAcc | P51589 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 1573 | CYP2J2 | HTA11_347_2000001011 | Human | Colorectum | AD | 2.15e-12 | 4.54e-01 | -0.1954 |
| 1573 | CYP2J2 | HTA11_99999970781_79442 | Human | Colorectum | MSS | 8.09e-15 | 6.75e-01 | 0.294 |
| 1573 | CYP2J2 | A015-C-203 | Human | Colorectum | FAP | 4.83e-05 | -1.18e-01 | -0.1294 |
| 1573 | CYP2J2 | A001-C-108 | Human | Colorectum | FAP | 1.01e-02 | -1.20e-01 | -0.0272 |
| 1573 | CYP2J2 | A002-C-205 | Human | Colorectum | FAP | 5.17e-03 | -1.79e-01 | -0.1236 |
| 1573 | CYP2J2 | A015-C-106 | Human | Colorectum | FAP | 2.21e-02 | -6.19e-02 | -0.0511 |
| 1573 | CYP2J2 | A015-C-104 | Human | Colorectum | FAP | 2.91e-06 | -1.63e-01 | -0.1899 |
| 1573 | CYP2J2 | A002-C-016 | Human | Colorectum | FAP | 1.65e-04 | -1.83e-01 | 0.0521 |
| 1573 | CYP2J2 | A001-C-203 | Human | Colorectum | FAP | 4.53e-02 | -1.08e-01 | -0.0481 |
| 1573 | CYP2J2 | A002-C-116 | Human | Colorectum | FAP | 9.27e-07 | -1.94e-01 | -0.0452 |
| 1573 | CYP2J2 | F034 | Human | Colorectum | FAP | 8.11e-05 | -1.31e-01 | -0.0665 |
| 1573 | CYP2J2 | CRC-3-11773 | Human | Colorectum | CRC | 9.30e-06 | -1.76e-01 | 0.2564 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0006631 | Colorectum | AD | fatty acid metabolic process | 114/3918 | 390/18723 | 5.58e-05 | 9.44e-04 | 114 |
| GO:0009410 | Colorectum | AD | response to xenobiotic stimulus | 128/3918 | 462/18723 | 2.69e-04 | 3.31e-03 | 128 |
| GO:00066312 | Colorectum | MSS | fatty acid metabolic process | 95/3467 | 390/18723 | 2.20e-03 | 1.84e-02 | 95 |
| GO:00094101 | Colorectum | MSS | response to xenobiotic stimulus | 110/3467 | 462/18723 | 2.36e-03 | 1.92e-02 | 110 |
| GO:00066313 | Colorectum | FAP | fatty acid metabolic process | 81/2622 | 390/18723 | 1.43e-04 | 2.24e-03 | 81 |
| GO:00094102 | Colorectum | FAP | response to xenobiotic stimulus | 87/2622 | 462/18723 | 2.15e-03 | 1.77e-02 | 87 |
| GO:00066314 | Colorectum | CRC | fatty acid metabolic process | 65/2078 | 390/18723 | 5.30e-04 | 7.42e-03 | 65 |
| GO:1903522 | Colorectum | CRC | regulation of blood circulation | 43/2078 | 256/18723 | 3.70e-03 | 3.12e-02 | 43 |
| GO:00094103 | Colorectum | CRC | response to xenobiotic stimulus | 69/2078 | 462/18723 | 6.34e-03 | 4.61e-02 | 69 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa05417 | Colorectum | AD | Lipid and atherosclerosis | 73/2092 | 215/8465 | 1.31e-03 | 8.27e-03 | 5.27e-03 | 73 |
| hsa054171 | Colorectum | AD | Lipid and atherosclerosis | 73/2092 | 215/8465 | 1.31e-03 | 8.27e-03 | 5.27e-03 | 73 |
| hsa054174 | Colorectum | MSS | Lipid and atherosclerosis | 70/1875 | 215/8465 | 2.38e-04 | 1.81e-03 | 1.11e-03 | 70 |
| hsa054175 | Colorectum | MSS | Lipid and atherosclerosis | 70/1875 | 215/8465 | 2.38e-04 | 1.81e-03 | 1.11e-03 | 70 |
| hsa054176 | Colorectum | FAP | Lipid and atherosclerosis | 54/1404 | 215/8465 | 8.04e-04 | 5.14e-03 | 3.13e-03 | 54 |
| hsa054177 | Colorectum | FAP | Lipid and atherosclerosis | 54/1404 | 215/8465 | 8.04e-04 | 5.14e-03 | 3.13e-03 | 54 |
| hsa054178 | Colorectum | CRC | Lipid and atherosclerosis | 45/1091 | 215/8465 | 5.73e-04 | 5.48e-03 | 3.72e-03 | 45 |
| hsa054179 | Colorectum | CRC | Lipid and atherosclerosis | 45/1091 | 215/8465 | 5.73e-04 | 5.48e-03 | 3.72e-03 | 45 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| CYP2J2 | SNV | Missense_Mutation | novel | c.283C>T | p.Pro95Ser | p.P95S | P51589 | protein_coding | tolerated(0.15) | benign(0.159) | TCGA-B6-A1KC-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| CYP2J2 | SNV | Missense_Mutation | novel | c.358N>G | p.Ile120Val | p.I120V | P51589 | protein_coding | tolerated(0.77) | benign(0.009) | TCGA-PL-A8LX-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| CYP2J2 | insertion | Frame_Shift_Ins | novel | c.732_733insTTCCCCAAAATTATAGG | p.Gln245PhefsTer16 | p.Q245Ffs*16 | P51589 | protein_coding | TCGA-AN-A0FX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| CYP2J2 | insertion | Nonsense_Mutation | novel | c.1123_1124insGGTGTGAGCCACTGCTTCTGACAGCTGTATAATTTATTAT | p.Ile375ArgfsTer11 | p.I375Rfs*11 | P51589 | protein_coding | TCGA-AO-A0J3-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | cyclophosphamide | SD | ||
| CYP2J2 | deletion | Frame_Shift_Del | c.1331_1356delNNNNNNNNNNNNNNNNNNNNNNNNNN | p.Gly444ValfsTer5 | p.G444Vfs*5 | P51589 | protein_coding | TCGA-AR-A256-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | PD | |||
| CYP2J2 | insertion | In_Frame_Ins | novel | c.1023_1024insAGTAGTTTTTCAACCCTTGCCCCACTCTCTCCTCCA | p.Ile341_Asp342insSerSerPheSerThrLeuAlaProLeuSerProPro | p.I341_D342insSSFSTLAPLSPP | P51589 | protein_coding | TCGA-BH-A0BV-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | doxorubicin | SD | ||
| CYP2J2 | deletion | Frame_Shift_Del | novel | c.524delG | p.Gly175AspfsTer38 | p.G175Dfs*38 | P51589 | protein_coding | TCGA-EW-A2FV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | SD | ||
| CYP2J2 | SNV | Missense_Mutation | novel | c.1429G>A | p.Glu477Lys | p.E477K | P51589 | protein_coding | tolerated(0.21) | benign(0.285) | TCGA-C5-A3HD-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD |
| CYP2J2 | SNV | Missense_Mutation | c.671C>T | p.Ser224Leu | p.S224L | P51589 | protein_coding | deleterious(0.01) | benign(0.41) | TCGA-Q1-A73O-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| CYP2J2 | SNV | Missense_Mutation | c.888N>A | p.Phe296Leu | p.F296L | P51589 | protein_coding | deleterious(0.03) | possibly_damaging(0.766) | TCGA-NH-A5IV-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 1573 | CYP2J2 | ENZYME, DRUGGABLE GENOME, CYTOCHROME P450 | terfenadine | TERFENADINE | 15861034 | |
| 1573 | CYP2J2 | ENZYME, DRUGGABLE GENOME, CYTOCHROME P450 | nabumetone | NABUMETONE | 19923256 | |
| 1573 | CYP2J2 | ENZYME, DRUGGABLE GENOME, CYTOCHROME P450 | thioridazine | THIORIDAZINE | 19923256 | |
| 1573 | CYP2J2 | ENZYME, DRUGGABLE GENOME, CYTOCHROME P450 | diclofenac | DICLOFENAC | 15861034 | |
| 1573 | CYP2J2 | ENZYME, DRUGGABLE GENOME, CYTOCHROME P450 | inhibitor | 252827489 | ||
| 1573 | CYP2J2 | ENZYME, DRUGGABLE GENOME, CYTOCHROME P450 | astemizole | ASTEMIZOLE | 15861034 | |
| 1573 | CYP2J2 | ENZYME, DRUGGABLE GENOME, CYTOCHROME P450 | albendazole | ALBENDAZOLE | 19923256 | |
| 1573 | CYP2J2 | ENZYME, DRUGGABLE GENOME, CYTOCHROME P450 | inhibitor | 135651245 | TERFENADINE | |
| 1573 | CYP2J2 | ENZYME, DRUGGABLE GENOME, CYTOCHROME P450 | danazol | DANAZOL | 19923256 | |
| 1573 | CYP2J2 | ENZYME, DRUGGABLE GENOME, CYTOCHROME P450 | mesoridazine | MESORIDAZINE | 19923256 |
| Page: 1 2 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |